In the Real World Study, the Efficacy and Adverse Reactions of Ticagrelor on Ischemic Cerebrovascular Disease

Launched by QIANFOSHAN HOSPITAL · Jan 29, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the medication ticagrelor, which is used to help prevent blood clots in patients with ischemic cerebrovascular disease, a condition that can lead to strokes. The main goal of the study is to understand how ticagrelor works in the body, how it relates to certain medical events like ischemia (when blood flow is reduced) and bleeding, and to assess its overall safety and effectiveness in treating this condition. Researchers plan to include at least 50 patients who are currently taking ticagrelor as part of their treatment.

To be eligible for this study, participants must be at least 18 years old and have been diagnosed with ischemic cerebrovascular disease. They should also be taking ticagrelor for their treatment and be able to provide their consent to participate. However, individuals with certain conditions, such as bleeding in the brain, serious diseases like tumors, or allergies to ticagrelor, will not be included. This trial is not yet recruiting participants, but once it begins, those who qualify can expect to contribute to important research that may improve treatment options for future patients with similar conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Female or male aged ≥ 18 years.
• • 2. Clinically diagnosed as ischemic cerebrovascular disease.
• • 3. Take ticagelor for antiplatelet therapy.
• • 4. Provision of informed consent.
• Exclusion Criteria:
• • 1. Head CT or MRI suggests the presence of intracranial hemorrhagic disease.
• • 2. People with tumors and other serious systemic diseases.
• • 3. Allergy to ticagelor.